Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Apologies slide c 35 mins gives forecast
mol
C6 hrs ago
We are delighted to have recently signed a new partnership agreement with Morepen for SlimBiome®!
‘We are pleased to announce this agreement with Morepen, a well-known and trusted supplier to pharmacies, physicians, and retail customers across India.
Morepen brings an extensive sales team with experience of highly differentiated scientific products and countrywide access to a network of around 500,000 pharmacies across India.
Based on current forecasts, the Directors anticipate this agreement could contribute in the region of £6-7 million revenue per annum in the next four to five years.’ – Stephen O’Hara, CEO of OptiBiotix
Let's wait and see what it actually generates in 2nd half 2024 and 1st half 2025 - mind we won't know former until probably this time next year (no rodders pun intended) and the latter probably not until full year 2025 disclosed ie circa may 2026
unless of course an indication given prior
i'm sure the forecasts didn't start from 4-5 years time
mol
i thought i read or listened on ************* somewhere he was confident of meeting the targets but we will see. they usually disappoint to the downside.
And well below c 1.75m forecast from may 2023 slides
mol
If so aquae considering
Strong first half of trading with sales of £351k (2022: £119k), a 195% increase over H1 2022. Given H1 2022 included £19.5k from Probiotic sales up to March 30 2022, the 'like for like' increase is 251%. 85% of this sales income was received in Q2 2023
and
“The aim for the second half of the year is to maintain our focus on managing costs, growing sales and closing out ongoing discussions with a number of larger partners across first and second-generation products to ensure a return on investment from the expansion of our commercial and business development teams. We are particularly excited about our second-generation products approaching commercialisation given their uniqueness in the marketplace. Our sweet prebiotic fibres, called SweetBiotix® create the opportunity to replace unhealthy calorific and cariogenic sugars with healthy fibres in a wide range of food and beverage products. With growing health concerns over traditional sugars and sweeteners, the commercialisation of SweetBiotix® meets a large global market need. After many years of hard work we are equally pleased at the significant progress we have made in 2023 in the manufacturing scale up our microbiome modulators which selectively enhance the growth rate of specific types of bacteria and create the potential for targeted treatment of a range of human diseases. We believe these unique products, individually and collectively, offer shareholders the potential for a significant enhancement in the value of the Company.
very disappointing outturn for 2023
albeit unfortunately i don't think your forecast figure is too far out
i really hope we are both wrong - not long to wait
mol
After opti being one of the most best performing shares on aim in 2023 - a fact Stephen but basically a calculating and selective statement disregarding the past
we had
PBX - must be one of the most undervalued shares on any market
jees really Stephen - twas yourself who listed same on probably the most illiquid market to save money apparently
and then at end of presentation you pushed any questions on PBX to either the company CEO or Walbrook which neatly
sidestepped any conversation regarding your previous comments re relisting on PBX on AIM albeit our
44% subsidiary with you on the Board of same - i take that as meaning any relisting not coming anytime soon
mind i also look forward with interest regarding the 100% owned subsidiary of pbx as undernoted
Probiotix Health Denmark ApS
As formed after year end no mention as a 100% subsidiary within our 31 dec 2022 financial statements
https://ownr-dk.translate.goog/companies/public-profile/43827774?_x_tr_sl=da&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
but presumably will be noted in our 2023 financial statements as a 100% subsidiary of our 44% interest
as to what the relevance its purpose has to probiotics or anything else to do with our 44% interest i'm at a loss
The purpose of the company
The company's purpose is to offer consultancy services linked to digital learning solutions and to sell digital learning platforms.
Number of employees
4 Employees (4 full-time, February 2024)
Steen the only Director
just a few observations on presentation
mol
Thanks AustinTexas.
By reintroducing the logo into yesterday's presentation, I guess we can assume all is not yet lost with Coca Cola.
Any reformulation would always be tested on a very small scale first, as the brand's way too valuable to risk reputational damage. Back in the 80s, Coca Cola launched "New Coke", only to have to abandon it months later & reintroduce the original formula under "Coca Cola Classic". They won't want to make the same mistake twice.
Not sure how they'd overcome the cloudiness issue though.
Coke was first mentioned about two years ago maybe longer, it’s not new news. SOH mentioned at the time that by adding Opti’s formula it made it cloudy. Also Coke are likely to launch the product on small scale to see how it’s received.
I submitted a question during the presentation about Coca Cola’s logo suddenly appearing on one of the slides.
But like both my other questions, it was ignored.
If anyone can shed any further light on this, I’d be grateful.
It potentially feels significant. But as someone already posted, it could just be SOH stringing us along, despite knowing the discussions came to nowt.
He also mentioned roles, which are manufactured by Nestlé with the exception of USA where Herschey makes them for Nestlé.
Coca-Cola logo front and centre
I personally thought it was a decent update showing the diversification in territories/sales and opportunities. Maybe the market didn't appreciate the Morepen deal enough. Roll on July and that being launched, it's a shame he couldn't say how much the first purchase order was when it was the biggest the company has had so far.
Confirmed the Coca Cola logo appears on the Summary slide which itself has been modified from the previous years slide entitled "World Presence and Partners".
Revenue excluding license fees and other is circa £645K for 2023 and forecast to be £1.5M for 2024
Lord, I recall CC being mentioned in the past by SOH. I think they have had discussions but nothing formalised. I would also suggest that if there is a formal dialogue then it would be via one of their US partners, not directly with Opti and very much under NDA.
Truth be known, most likely one of the many carrots that SOH has a tendency to dangling under PIs' noses!! Well known name, zero substance!!
Thx lord and aquae for the updates
Extremely disappointing but unfortunately not unexpected
Also a mention in sweetbiotix update from last year
https://www.optibiotix-ir.com/content/news/archive/2023/190723
Hopefully slides available soon
Many thanks again
mol
Missed the logo so will need to revisit the slides once available but if it is the same slide as used in the May 2023 Presentation entitled "World Presence and Partners" then just randomly plucked from the list of 11 or so Companies with MTA agreements for Sweetbiotix. One slide I will be taking a closer look at lists the Revenue actuals for 2023
AquaeSulis01 & rebarm - glad it wasn't just me!
Can either of you shed any light on the Coca Cola logo that appeared prominently on top of one of the slides?
No change....patronising waffle!
Agree with you loads, SOH spent 50 minutes on the presentation mainly trying to justify the benefits of Slimbiome to investors when it would have been better aimed at Customers, and that left only 10 minutes to address questions which were generically answered. No in-flight questions were looked at and none of my three pre-submitted questions were addressed by the generic responses, total waste of time.
Most/all the trickier questions from me (& others on here) were carefully ignored this afternoon. Wonder why?!
Well, they asked for feedback at the end, so I gave them plenty.
All pretty disapponting IMHO, with little to get your teeth into other than noncommittal sales projections, vague timelines & jam tomorrow statements.
Talking of leading US partners one minute, then projecting sales in the low £millions from them by year 5 just didn't stack up for me.
On a potentially more optimistic note, what was the Coca Cola logo doing on one of the slides? Have I missed something?
OPTIBIOTIX HEALTH PLC will be holding the meeting Commercial update tomorrow at 20th May 2024 at 2:00pm BST.
Because as a seedcorn fund their policy is to withdraw funding after the early stages whatever in order to move funds to new early stage companies; the policy over-rides the financial considerations.
I’d be as interested to know why Finance Yorkshire Seedcorn Fund is selling down its position, when Opti’s share price is currently so depressed anyway.
But I guess SOH may not know that. Or want to reveal it even if he does….